Cogent Biosciences, Inc. (COGT) stock
COGTNasdaqPharmaceutical PreparationsFiscal year ends December 31
$27.85+0.41 (+1.49%)
Close on Nov 17, 2026Market cap $4.83BP/E –Yield –
Cogent Biosciences r&d expenses
Research and development expenses are spending on new products and technology.
Cogent Biosciences's R&D Expenses for the twelve months ending Jun 30, 2026 was $290.72M, up 15.9% year over year. For fiscal 2025 it was $269.78M, up 16.0% from the year before. The highest annual figure on record is $269.78M in fiscal 2025.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $269.78M | +16.0% |
| FY2024 | Dec 31, 2024 | $232.66M | +33.9% |
| FY2023 | Dec 31, 2023 | $173.76M | +42.9% |
| FY2022 | Dec 31, 2022 | $121.63M | +117.5% |
| FY2021 | Dec 31, 2021 | $55.91M | +117.2% |
| FY2020 | Dec 31, 2020 | $25.74M | -41.1% |
| FY2019 | Dec 31, 2019 | $43.71M | +14.2% |
| FY2018 | Dec 31, 2018 | $38.29M | +28.3% |
| FY2017 | Dec 31, 2017 | $29.83M | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $70.81M | +13.8% |
| Q1 FY2026 | Mar 31, 2026 | $75.37M | +19.6% |
| Q4 FY2025 | Dec 31, 2025 | $75.56M | +21.8% |
| Q3 FY2025 | Sep 30, 2025 | $68.99M | +8.4% |
| Q2 FY2025 | Jun 30, 2025 | $62.20M | +14.6% |
| Q1 FY2025 | Mar 31, 2025 | $63.03M | +19.6% |
| Q4 FY2024 | Dec 31, 2024 | $62.05M | +27.4% |
| Q3 FY2024 | Sep 30, 2024 | $63.61M | +26.9% |
| Q2 FY2024 | Jun 30, 2024 | $54.29M | +39.7% |
| Q1 FY2024 | Mar 31, 2024 | $52.71M | +46.2% |
| Q4 FY2023 | Dec 31, 2023 | $48.72M | +32.6% |
| Q3 FY2023 | Sep 30, 2023 | $50.13M | +67.4% |
| Q2 FY2023 | Jun 30, 2023 | $38.87M | +31.9% |
| Q1 FY2023 | Mar 31, 2023 | $36.04M | +41.5% |
| Q4 FY2022 | Dec 31, 2022 | $36.74M | +79.1% |
| Q3 FY2022 | Sep 30, 2022 | $29.94M | +102.3% |
| Q2 FY2022 | Jun 30, 2022 | $29.48M | +138.0% |
| Q1 FY2022 | Mar 31, 2022 | $25.47M | +210.1% |
| Q4 FY2021 | Dec 31, 2021 | $20.51M | +235.9% |
| Q3 FY2021 | Sep 30, 2021 | $14.80M | +195.8% |
| Q2 FY2021 | Jun 30, 2021 | $12.39M | +141.5% |
| Q1 FY2021 | Mar 31, 2021 | $8.21M | -13.5% |
| Q4 FY2020 | Dec 31, 2020 | $6.11M | -41.0% |
| Q3 FY2020 | Sep 30, 2020 | $5.00M | -51.6% |
| Q2 FY2020 | Jun 30, 2020 | $5.13M | -51.7% |
| Q1 FY2020 | Mar 31, 2020 | $9.50M | -23.4% |
| Q4 FY2019 | Dec 31, 2019 | $10.35M | -3.8% |
| Q3 FY2019 | Sep 30, 2019 | $10.34M | +0.8% |
| Q2 FY2019 | Jun 30, 2019 | $10.62M | +16.3% |
| Q1 FY2019 | Mar 31, 2019 | $12.40M | +52.3% |
| Q4 FY2018 | Dec 31, 2018 | $10.77M | +42.4% |
| Q3 FY2018 | Sep 30, 2018 | $10.25M | +25.4% |
| Q2 FY2018 | Jun 30, 2018 | $9.13M | +27.8% |
| Q1 FY2018 | Mar 31, 2018 | $8.14M | +17.1% |
| Q4 FY2017 | Dec 31, 2017 | $7.56M | – |
| Q3 FY2017 | Sep 30, 2017 | $8.18M | – |
| Q2 FY2017 | Jun 30, 2017 | $7.14M | – |
| Q1 FY2017 | Mar 31, 2017 | $6.95M | – |
See a number that looks wrong?